ELISA/assay

Hamster apolipoprotein B, APOB ELISA Kit

MBS907181

96-Strip-Wells

630 USD

ELISA Kit

Hamster apolipoprotein B, APOB ELISA Kit

apolipoprotein B (APOB)

Hamster apolipoprotein B (APOB) ELISA kit; Hamster apolipoprotein B (APOB)

apolipoprotein B-100; Apolipoprotein B-100; apolipoprotein B-100; apoB-48; apoB-100; apo B-100; mutant Apo B 100; apolipoprotein B48; apolipoprotein B (including Ag(x) antigen); apolipoprotein B

APOB

APOB; APOB; FLDB; LDLCQ4; Apo B-100; Apo B-48

APOB_HUMAN

Hamster

4563

This assay has high sensitivity and excellent specificity for detection of Hamster APOB. No significant cross-reactivity or interference between Hamster APOB and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma and tissue homogenates. Detection Range: 0.313ug/ml-20 ug/ml. Sensitivity: 0.372 ug/ml

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV% is less than 8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision (Precision between assays): CV% is less than 10%. Three samples of known concentration were tested in twenty assays to assess. Protein Biological Process 1: Apolipoprotein

Principle of the Assay: The microtiter plate provided in this kit has been pre-coated with an antibody specific to APOB Standards or samples are then added to the appropriate microtiter plate wells with a HRP-conjugated antibody preparation specific for APOB to each microplate well and incubated. Then a TMB (3,3',5,5' tetramethyl-benzidine) substrate solution is added to each well. Only those wells that contain APOB, HRP-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm +/- 2 nm. The concentration of APOB in the samples is then determined by comparing the O.D. of the samples to the standard curve.

105990532

NP_000375.2

NM_000384.2

P04114

515,605 Da

Cell Surface Interactions At The Vascular Wall Pathway (106062); Chylomicron-mediated Lipid Transport Pathway (106157); FOXA1 Transcription Factor Network Pathway (137979); Fat Digestion And Absorption Pathway (194385); Fat Digestion And Absorption Pathway (194324); Hemostasis Pathway (106028); LDL-mediated Lipid Transport Pathway (106159); Lipid Digestion, Mobilization, And Transport Pathway (106111); Lipoprotein Metabolism Pathway (106156); Metabolism Pathway (477135)

This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA- UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Jul 2008]

APOB: Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Defects in APOB are a cause of familial hypobetalipoproteinemia type 1 (FHBL1). A disorder characterized by highly reduced plasma concentrations of low density lipoproteins, and dietary fat malabsorption. Clinical presentation may vary from no symptoms to severe gastrointestinal and neurological dysfunction similar to abetalipoproteinemia. Defects in APOB are a cause of familial ligand-defective apolipoprotein B-100 (FDB). FDB is a dominantly inherited disorder of lipoprotein metabolism leading to hypercholesterolemia and increased proneness to coronary artery disease (CAD). The plasma cholesterol levels are dramatically elevated due to impaired clearance of LDL particles by defective APOB/E receptors. Defects in APOB associated with defects in other genes (polygenic) can contribute to hypocholesterolemia. Protein type: Secreted; Secreted, signal peptide; Carrier. Chromosomal Location of Human Ortholog: 2p24-p23. Cellular Component: Golgi apparatus; extracellular space; endoplasmic reticulum membrane; intracellular membrane-bound organelle; endoplasmic reticulum lumen; early endosome; extracellular region; cytosol; actin cytoskeleton; chylomicron; cell soma; cytoplasm; plasma membrane; endosome membrane. Molecular Function: heparin binding; protein binding; low-density lipoprotein receptor binding; cholesterol transporter activity; phospholipid binding. Biological Process: lipoprotein catabolic process; phototransduction, visible light; response to lipopolysaccharide; response to carbohydrate stimulus; post-embryonic development; response to selenium ion; triacylglycerol catabolic process; retinoid metabolic process; transmembrane transport; receptor-mediated endocytosis; cholesterol metabolic process; nervous system development; cholesterol transport; in utero embryonic development; response to virus; regulation of cholesterol biosynthetic process; lipoprotein metabolic process; cholesterol efflux; cholesterol homeostasis; sperm motility; fertilization; lipoprotein biosynthetic process; lipoprotein transport; artery morphogenesis; spermatogenesis; blood coagulation; triacylglycerol mobilization; leukocyte migration. Disease: Hypercholesterolemia, Autosomal Dominant, Type B; Hypobetalipoproteinemia, Familial, 1

96-Strip-Wells

630 USD

5x96-Strip-Wells

1955

10x96-Strip-Wells

3635